Form 4: Agilon Health Executive Reports Stock Transactions

Girish Venkatachaliah, Chief Technology Officer at Agilon Health, Inc., reported transactions involving common stock and restricted stock units.

Summary

• Girish Venkatachaliah, Chief Technology Officer at Agilon Health, Inc. (AGL), reported a transaction on April 1, 2026.
• 480 shares of Common Stock were disposed of at a price of $9.75, resulting in 10,662 shares beneficially owned.
• Additionally, 28,000 restricted stock units (RSUs) were acquired at no cost, bringing the total beneficially owned securities to 38,662.
• The RSUs vest in three equal installments annually starting April 1, 2026, contingent on continued employment.
• The reported securities ownership reflects a 1-for-25 reverse stock split effective March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reflecting routine executive compensation and tax-related stock disposals rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of 28,000 restricted stock units, indicating continued incentive for key personnel.
• The vesting schedule for RSUs provides a retention incentive for the Chief Technology Officer.

Negatives

• Disposition of 480 shares of common stock, although the context suggests it was for tax withholding.
• The disposal price of $9.75 per share is noted, but its implication is limited due to the tax withholding nature.

Risks

• The vesting of RSUs is subject to continued employment, implying a risk of forfeiture if employment ceases.
• The reverse stock split, while a corporate action, can sometimes be perceived negatively by the market if not accompanied by fundamental improvements.

Future Outlook

The restricted stock units acquired are set to vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment, indicating a structured incentive plan for the future.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported activity, particularly the acquisition of RSUs and the tax withholding disposal, is typical for executive compensation and compliance within the healthcare technology sector.

Stakeholder Impact

• Shareholders: The transaction is an insider filing and does not directly indicate a change in the company's fundamental value, though it reflects executive compensation practices.
• Employees: The vesting of RSUs reinforces employee retention incentives for key personnel.
• Management: The transaction is part of the executive's compensation and tax management.

Next Steps

• Vesting of restricted stock units in three equal installments on each anniversary of April 1, 2026, contingent on continued employment.

Key Dates

Keywords

Form 4, SEC Filing, Agilon Health, AGL, Girish Venkatachaliah, Stock Transaction, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Reverse Stock Split, Insider Trading, Executive Compensation